VivoSim Labs, INC. (ONVO) Stock Forecast 2025 - AI Price Prediction & Analysis

Q: What factors influence VivoSim Labs, INC. stock price forecasts?

Our analysis considers financial metrics, sector trends, market sentiment, technical indicators, and macroeconomic factors.

VivoSim Labs, INC. (ONVO) AI Stock Price Forecast & Investment Analysis

Latest Analysis Date: Mei 02, 2025

Loading VivoSim Labs, INC. interactive price chart and technical analysis...

VivoSim Labs, INC. (ONVO) - Comprehensive Stock Analysis & Investment Research

Deep dive into VivoSim Labs, INC.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about VivoSim Labs, INC., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For VivoSim Labs, INC.: VivoSim Labs, INC. operates in the Life Sciences sector, making it an emerging small-cap investment.

VivoSim Labs, INC. (Stock Symbol: ONVO) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry.

The organization employs approximately 6 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing VivoSim Labs, INC.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For VivoSim Labs, INC.: With $1M in annual revenue and -1135,0% net margin, the company demonstrates developing profitability.

Annual Revenue: $1 million generating a -1135,0% net profit margin .

Market Capitalization: $35 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -33,0% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for VivoSim Labs, INC. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For VivoSim Labs, INC.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for VivoSim Labs, INC. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: VivoSim Labs, INC.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For VivoSim Labs, INC.: Market positioning analysis based on available financial and operational metrics.

VivoSim Labs, INC. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 85,1% gross margin, indicating strong pricing power and operational efficiency.

VivoSim Labs, INC. (ONVO) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for VivoSim Labs, INC. stock analysis.

Loading VivoSim Labs, INC. comprehensive fundamental analysis and insider trading data...

Deep dive into VivoSim Labs, INC.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if VivoSim Labs, INC. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For VivoSim Labs, INC.: With a P/E ratio of -0,36, the market sees the stock as potentially undervalued.

P/E Ratio -0,36x

P/B Ratio 95,90x

Market Cap $35M

EPS $-1,05

Book Value/Share $0,02

Revenue/Share $0,06

FCF/Share $-2,22

Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently VivoSim Labs, INC. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For VivoSim Labs, INC.: An ROE of -33,0% indicates room for improvement in shareholder value creation.

ROE -33,0%

ROA -31,3%

ROIC -31,1%

Gross Margin 85,1%

Operating Margin -1155,7%

Net Margin -1135,0%

EBT Margin -763,1%

Understanding Financial Health Metrics

What these metrics mean: These ratios assess VivoSim Labs, INC.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For VivoSim Labs, INC.: A current ratio of 21,35 indicates strong liquidity.

Current Ratio 21,35x

Quick Ratio 20,73x

D/E Ratio 0,06x

Financial Leverage 1,10x

Interest Coverage -39,0x

Working Capital $38M

Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal VivoSim Labs, INC.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For VivoSim Labs, INC.: Free cash flow of $-9M indicates cash challenges that need attention.

Operating Cash Flow $-8M

Free Cash Flow $-9M

FCF/Sales -590,8%

CapEx/Sales 27,3%

Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively VivoSim Labs, INC. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For VivoSim Labs, INC.: An asset turnover of 0,04x suggests room for improvement in asset utilization.

Asset Turnover 0,04x

Receivables Turnover 7,2x

Inventory Turnover 1,3x

Fixed Assets Turnover 0,9x

Days Sales Outstanding 51 days

Days Inventory 273 days

Payables Period 750 days

Cash Conversion Cycle -426 days

Understanding Financial Statement Data

What these metrics mean: Key figures from VivoSim Labs, INC.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For VivoSim Labs, INC.: With annual revenue of $1M, VivoSim Labs, INC. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)

Total Revenue $1M

Operating Income $-12M

Net Income $-12M

R&D Expense $5M

SG&A Expense $642M

Balance Sheet Highlights (% Of Assets)

Total Current Assets 89%

Cash & Short-term Investments 86%

Total Liabilities 9%

Accounts Receivable 0%

Inventory 1%

Dividend & Shareholder Information

Shares Outstanding 17M

Growth Metrics (YoY)

EPS Growth -228,3%

Latest VivoSim Labs, INC. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting VivoSim Labs, INC. (ONVO) stock price and investment outlook.

VivoSim Labs Inc

4mon ago, source: CNN

View VivoSim Labs Inc VIVS stock quote prices, financial information, real-time forecasts, and company news from CNN.

VIVS - VivoSim Labs Inc Key Metrics | Morningstar

2mon ago, source: Morningstar

Review the current VivoSim Labs Inc (VIVS:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if VIVS is the best investment for you.

VIVS Stock Quote Price and Forecast | CNN

4mon ago, source: CNN

View VivoSim Labs Inc VIVS stock quote prices, financial information, real-time forecasts, and company news from CNN.

VIVS - VivoSim Labs Inc Valuation | Morningstar

3mon ago, source: Morningstar

Review the current valuation for VivoSim Labs Inc (VIVS:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

VivoSim Labs, Inc. Common Stock (VIVS) Financials - Nasdaq

6d ago, source: Nasdaq

Find the latest VivoSim Labs, Inc. Common Stock (VIVS) annual income statements, balance sheets, financial statements, ratios, and cash flow data at Nasdaq.com.

VivoSim to Carry Forward Organovo 3D Bioprinting - Nasdaq

4mon ago, source: Nasdaq

--Organovo Holdings, Inc. announced that it will carry forward its 3 D bioprinting and legacy technology as VivoSim Labs, Inc.. A name change of the Company to VivoSim Labs, Inc. will be effective ...

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

26d ago, source: Fox2Now St. Louis

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on ...

VivoSim Labs, Inc. (VIVS) Income Statement - Yahoo Finance

4mon ago, source: Yahoo Finance

Get the detailed quarterly/annual income statement for VivoSim Labs, Inc. (VIVS). Find out the revenue, expenses and profit or loss over the last fiscal year.

VivoSim: Fiscal Q1 Earnings Snapshot - Yahoo Finance

28d ago, source: Yahoo Finance

SAN DIEGO (AP) — VivoSim Labs, Inc. VIVS) on Tuesday reported a loss of $2.8 million in its fiscal first quarter. On a per-share basis, the San Diego-based company said it had a loss of $1.14.

VivoSim: Fiscal Q1 Earnings Snapshot - Chron

28d ago, source: Houston Chronicle

SAN DIEGO (AP) — SAN DIEGO (AP) — VivoSim Labs, Inc. (VIVS) on Tuesday reported a loss of $2.8 million in its fiscal first quarter.

VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief ...

26d ago, source: Finanznachrichten

VivoSim Labs, Inc. ("VivoSim" and the "Company"), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D ...

VivoSim Labs, INC. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of VivoSim Labs, INC. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company	Ticker Symbol	90-Day AI Forecast	Market Cap (USD M)	P/E Ratio	P/B Ratio
Acumen Pharmaceuticals, Inc.	ABOS	Unlock Forecast - 30 Days FREE Trial	$85M	-1,9x	0,7x
Abpro Holdings, Inc.	ABP	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Abpro Holdings, Inc.	ABPWW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Arcellx, Inc.	ACLX	Unlock Forecast - 30 Days FREE Trial	$3725M	-74,1x	8,9x
Alpha Cognition Inc.	ACOG	Unlock Forecast - 30 Days FREE Trial	$143M	x	4,5x
Adaptimmune Therapeutics PLC	ADAP	Unlock Forecast - 30 Days FREE Trial	$65M	-13,2x	-11,8x
ADMA BIOLOGICS, INC.	ADMA	Unlock Forecast - 30 Days FREE Trial	$4035M	19,3x	10,1x
Adaptive Biotechnologies Corp	ADPT	Unlock Forecast - 30 Days FREE Trial	$1901M	-4,6x	10,6x
Adverum Biotechnologies, Inc.	ADVM	Unlock Forecast - 30 Days FREE Trial	$58M	-1,8x	2,2x
AGENUS INC	AGEN	Unlock Forecast - 30 Days FREE Trial	$130M	-0,5x	-0,5x
AIM ImmunoTech Inc.	AIM	Unlock Forecast - 30 Days FREE Trial	$2M	-0,5x	-183,3x
AIM ImmunoTech Inc.	AIMI	Unlock Forecast - 30 Days FREE Trial	$2M	x	x
Alector, Inc.	ALEC	Unlock Forecast - 30 Days FREE Trial	$305M	-1,2x	4,3x
Aligos Therapeutics, Inc.	ALGS	Unlock Forecast - 30 Days FREE Trial	$107M	-19,2x	1,1x
Allogene Therapeutics, Inc.	ALLO	Unlock Forecast - 30 Days FREE Trial	$253M	-1,4x	0,7x
Kalaris Therapeutics, Inc.	ALVR	Unlock Forecast - 30 Days FREE Trial	$49M	-0,5x	0,4x
AMGEN INC	AMGN	Unlock Forecast - 30 Days FREE Trial	$151583M	22,9x	20,4x
Apogee Therapeutics, Inc.	APGE	Unlock Forecast - 30 Days FREE Trial	$2240M	-20,5x	4,3x
Aptose Biosciences Inc.	APTO	Unlock Forecast - 30 Days FREE Trial	$6M	0,0x	-1,3x
Aptose Biosciences Inc.	APTOF	Unlock Forecast - 30 Days FREE Trial	$3M	x	x
Armata Pharmaceuticals, Inc.	ARMP	Unlock Forecast - 30 Days FREE Trial	$103M	-1,0x	-1,6x
Artiva Biotherapeutics, Inc.	ARTV	Unlock Forecast - 30 Days FREE Trial	$88M	x	0,6x
Athira Pharma, Inc.	ATHA	Unlock Forecast - 30 Days FREE Trial	$15M	-0,2x	0,5x
Atara Biotherapeutics, Inc.	ATRA	Unlock Forecast - 30 Days FREE Trial	$149M	25,8x	-1,1x
aTYR PHARMA INC	ATYR	Unlock Forecast - 30 Days FREE Trial	$515M	-3,6x	6,9x
Aura Biosciences, Inc.	AURA	Unlock Forecast - 30 Days FREE Trial	$402M	-4,9x	2,3x
Autolus Therapeutics plc	AUTL	Unlock Forecast - 30 Days FREE Trial	$389M	x	1,1x
ANAVEX LIFE SCIENCES CORP.	AVXL	Unlock Forecast - 30 Days FREE Trial	$803M	-17,3x	8,8x
BioAtla, Inc.	BCAB	Unlock Forecast - 30 Days FREE Trial	$125M	-1,1x	1,0x
BioCardia, Inc.	BCDA	Unlock Forecast - 30 Days FREE Trial	$12M	-0,6x	-7,8x
BRAINSTORM CELL THERAPEUTICS INC.	BCLI	Unlock Forecast - 30 Days FREE Trial	$7M	-4,9x	-0,9x
BIOCRYST PHARMACEUTICALS INC	BCRX	Unlock Forecast - 30 Days FREE Trial	$1802M	-12,1x	-4,0x
Black Diamond Therapeutics, Inc.	BDTX	Unlock Forecast - 30 Days FREE Trial	$171M	11,8x	1,3x
Beam Therapeutics Inc.	BEAM	Unlock Forecast - 30 Days FREE Trial	$1979M	-12,6x	1,9x
BIOGEN INC.	BIIB	Unlock Forecast - 30 Days FREE Trial	$18125M	12,8x	1,5x
Black Hawk Acquisition Corp	BKHA	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Black Hawk Acquisition Corp	BKHAU	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
bluebird bio, Inc.	BLUE	Unlock Forecast - 30 Days FREE Trial	$49M	-0,2x	-0,8x
Cabaletta Bio, Inc.	CABA	Unlock Forecast - 30 Days FREE Trial	$155M	-1,6x	0,9x
Candel Therapeutics, Inc.	CADL	Unlock Forecast - 30 Days FREE Trial	$338M	-4,6x	4,5x
C4 Therapeutics, Inc.	CCCC	Unlock Forecast - 30 Days FREE Trial	$193M	-2,6x	1,1x
Cidara Therapeutics, Inc.	CDTX	Unlock Forecast - 30 Days FREE Trial	$728M	-1,0x	5,1x
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.	CELZ	Unlock Forecast - 30 Days FREE Trial	$9M	-3,4x	1,3x
CERO THERAPEUTICS HOLDINGS, INC.	CERO	Unlock Forecast - 30 Days FREE Trial	$2M	x	-196,2x
CERO THERAPEUTICS HOLDINGS, INC.	CEROW	Unlock Forecast - 30 Days FREE Trial	$2M	x	-0,5x
Cullinan Therapeutics, Inc.	CGEM	Unlock Forecast - 30 Days FREE Trial	$449M	-4,1x	0,8x
COMPUGEN LTD	CGEN	Unlock Forecast - 30 Days FREE Trial	$134M	x	2,7x
CG Oncology, Inc.	CGON	Unlock Forecast - 30 Days FREE Trial	$2502M	x	3,7x
COGNITION THERAPEUTICS INC	CGTX	Unlock Forecast - 30 Days FREE Trial	$170M	-0,5x	24,1x
Pelthos Therapeutics Inc.	CHRO	Unlock Forecast - 30 Days FREE Trial	$8M	x	-2,0x
Coherus Oncology, Inc.	CHRS	Unlock Forecast - 30 Days FREE Trial	$150M	0,8x	1,3x
Calidi Biotherapeutics, Inc.	CLDI	Unlock Forecast - 30 Days FREE Trial	$5M	-0,9x	3,1x
Compass Therapeutics, Inc.	CMPX	Unlock Forecast - 30 Days FREE Trial	$483M	-4,8x	5,2x
Coeptis Therapeutics Holdings, Inc.	COEPW	Unlock Forecast - 30 Days FREE Trial	$M	x	x
Caribou Biosciences, Inc.	CRBU	Unlock Forecast - 30 Days FREE Trial	$174M	-1,5x	1,1x
Cardiff Oncology, Inc.	CRDF	Unlock Forecast - 30 Days FREE Trial	$144M	-4,0x	2,5x
CARGO Therapeutics, Inc.	CRGX	Unlock Forecast - 30 Days FREE Trial	$215M	x	0,9x
CURIS INC	CRIS	Unlock Forecast - 30 Days FREE Trial	$18M	-0,3x	-2,9x
CRISPR Therapeutics AG	CRSP	Unlock Forecast - 30 Days FREE Trial	$4781M	-12,1x	2,8x
CHAMPIONS ONCOLOGY, INC.	CSBR	Unlock Forecast - 30 Days FREE Trial	$111M	-17,8x	20,4x
CEL SCI CORP	CVM	Unlock Forecast - 30 Days FREE Trial	$56M	-0,9x	8,0x
Cyclo Therapeutics, Inc.	CYTH	Unlock Forecast - 30 Days FREE Trial	$26M	-0,6x	-1,9x
Cyclo Therapeutics, Inc.	CYTHW	Unlock Forecast - 30 Days FREE Trial	$7M	x	-0,5x
DBV Technologies S.A.	DBVT	Unlock Forecast - 30 Days FREE Trial	$1479M	-3,3x	514,8x
Ginkgo Bioworks Holdings, Inc.	DNA	Unlock Forecast - 30 Days FREE Trial	$568M	-13,9x	0,3x
Denali Therapeutics Inc.	DNLI	Unlock Forecast - 30 Days FREE Trial	$2111M	-8,7x	1,9x
PRECISION BIOSCIENCES INC	DTIL	Unlock Forecast - 30 Days FREE Trial	$59M	-2,2x	1,7x
DYADIC INTERNATIONAL INC	DYAI	Unlock Forecast - 30 Days FREE Trial	$28M	-7,3x	11,4x
Editas Medicine, Inc.	EDIT	Unlock Forecast - 30 Days FREE Trial	$231M	-0,8x	3,7x
Elevation Oncology, Inc.	ELEV	Unlock Forecast - 30 Days FREE Trial	$22M	-1,0x	0,5x
ELUTIA INC.	ELUT	Unlock Forecast - 30 Days FREE Trial	$84M	-1,4x	-0,1x
enGene Holdings Inc.	ENGN	Unlock Forecast - 30 Days FREE Trial	$276M	3,7x	1,2x
enGene Holdings Inc.	ENGNW	Unlock Forecast - 30 Days FREE Trial	$37M	x	0,1x
Entera Bio Ltd.	ENTX	Unlock Forecast - 30 Days FREE Trial	$94M	8,5x	5,4x
ENZO BIOCHEM INC	ENZ	Unlock Forecast - 30 Days FREE Trial	$25M	-3,0x	0,5x
ENZO BIOCHEM INC	ENZB	Unlock Forecast - 30 Days FREE Trial	$37M	x	0,8x
Estrella Immunopharma, Inc.	ESLA	Unlock Forecast - 30 Days FREE Trial	$39M	-3,1x	-16,9x
Estrella Immunopharma, Inc.	ESLAW	Unlock Forecast - 30 Days FREE Trial	$4M	x	5,3x
EXELIXIS, INC.	EXEL	Unlock Forecast - 30 Days FREE Trial	$10790M	17,9x	5,3x
EXOZYMES INC.	EXOZ	Unlock Forecast - 30 Days FREE Trial	$100M	x	13,9x
FATE THERAPEUTICS INC	FATE	Unlock Forecast - 30 Days FREE Trial	$115M	-1,3x	0,4x
4D Molecular Therapeutics, Inc.	FDMT	Unlock Forecast - 30 Days FREE Trial	$406M	-3,0x	1,0x
FENNEC PHARMACEUTICALS INC.	FENC	Unlock Forecast - 30 Days FREE Trial	$250M	1758,3x	-39,7x
Finch Therapeutics Group, Inc.	FNCH	Unlock Forecast - 30 Days FREE Trial	$20M	-0,1x	1,4x
FutureTech II Acquisition Corp.	FTII	Unlock Forecast - 30 Days FREE Trial	$-26M	x	-0,7x
FutureTech II Acquisition Corp.	FTIIU	Unlock Forecast - 30 Days FREE Trial	$-26M	x	-0,8x
FutureTech II Acquisition Corp.	FTIIW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
GILEAD SCIENCES, INC.	GILD	Unlock Forecast - 30 Days FREE Trial	$145661M	23,1x	7,4x
Monte Rosa Therapeutics, Inc.	GLUE	Unlock Forecast - 30 Days FREE Trial	$398M	16,5x	1,5x
Genenta Science S.p.A.	GNTA	Unlock Forecast - 30 Days FREE Trial	$64M	x	5,1x
Green Planet Bio Engineering Co. Ltd.	GPLB	Unlock Forecast - 30 Days FREE Trial	$M	x	x
HALOZYME THERAPEUTICS, INC.	HALO	Unlock Forecast - 30 Days FREE Trial	$9516M	17,1x	28,6x
HilleVax, Inc.	HLVX	Unlock Forecast - 30 Days FREE Trial	$105M	-0,6x	0,7x
Humacyte, Inc.	HUMA	Unlock Forecast - 30 Days FREE Trial	$224M	-3,3x	55,2x
Humacyte, Inc.	HUMAW	Unlock Forecast - 30 Days FREE Trial	$163M	x	-2,6x
ImmunityBio, Inc.	IBRX	Unlock Forecast - 30 Days FREE Trial	$2427M	-3,6x	-4,1x
Ikena Oncology, Inc.	IKNA	Unlock Forecast - 30 Days FREE Trial	$61M	-1,3x	0,5x
Inhibikase Therapeutics, Inc.	IKT	Unlock Forecast - 30 Days FREE Trial	$150M	-1,0x	1,9x
Immunocore Holdings plc	IMCR	Unlock Forecast - 30 Days FREE Trial	$1827M	x	4,7x
Immunovant, Inc.	IMVT	Unlock Forecast - 30 Days FREE Trial	$2803M	-14,5x	4,6x
IN8BIO, INC.	INAB	Unlock Forecast - 30 Days FREE Trial	$21M	-0,4x	2,4x
Inhibrx Biosciences, Inc.	INBX	Unlock Forecast - 30 Days FREE Trial	$436M	-6,8x	6,4x
MiNK Therapeutics, Inc.	INKT	Unlock Forecast - 30 Days FREE Trial	$59M	-1,5x	-1,4x
Inmune Bio, Inc.	INMB	Unlock Forecast - 30 Days FREE Trial	$52M	-2,5x	1,8x
INTENSITY THERAPEUTICS, INC.	INTS	Unlock Forecast - 30 Days FREE Trial	$7M	-2,2x	3,4x
IOVANCE BIOTHERAPEUTICS, INC.	IOVA	Unlock Forecast - 30 Days FREE Trial	$851M	-4,5x	1,2x
Century Therapeutics, Inc.	IPSC	Unlock Forecast - 30 Days FREE Trial	$44M	-0,7x	0,2x
iTeos Therapeutics, Inc.	ITOS	Unlock Forecast - 30 Days FREE Trial	$393M	-2,8x	0,7x
Invivyd, Inc.	IVVD	Unlock Forecast - 30 Days FREE Trial	$137M	-0,4x	3,2x
EXOZYMES INC.	IZTC	Unlock Forecast - 30 Days FREE Trial	$99M	x	-27,5x
Jasper Therapeutics, Inc.	JSPR	Unlock Forecast - 30 Days FREE Trial	$44M	-3,2x	1,9x
Jasper Therapeutics, Inc.	JSPRW	Unlock Forecast - 30 Days FREE Trial	$3M	x	0,0x
Kalaris Therapeutics, Inc.	KLRS	Unlock Forecast - 30 Days FREE Trial	$86M	x	1,6x
Klotho Neurosciences, Inc.	KLTO	Unlock Forecast - 30 Days FREE Trial	$26M	x	2,4x
Klotho Neurosciences, Inc.	KLTOW	Unlock Forecast - 30 Days FREE Trial	$1M	x	0,4x
Kodiak Sciences Inc.	KOD	Unlock Forecast - 30 Days FREE Trial	$556M	-2,5x	7,9x
Kiromic Biopharma, Inc.	KRBPQ	Unlock Forecast - 30 Days FREE Trial	$0M	x	x
Krystal Biotech, Inc.	KRYS	Unlock Forecast - 30 Days FREE Trial	$4330M	29,5x	4,2x
Kymera Therapeutics, Inc.	KYMR	Unlock Forecast - 30 Days FREE Trial	$3533M	-17,8x	3,6x
Kyverna Therapeutics, Inc.	KYTX	Unlock Forecast - 30 Days FREE Trial	$170M	x	0,9x
LadRx Corp	LADX	Unlock Forecast - 30 Days FREE Trial	$M	x	x
Lineage Cell Therapeutics, Inc.	LCTX	Unlock Forecast - 30 Days FREE Trial	$271M	-4,7x	5,6x
LENZ Therapeutics, Inc.	LENZ	Unlock Forecast - 30 Days FREE Trial	$1196M	-6,7x	5,8x
Liminatus Pharma, Inc.	LIMN	Unlock Forecast - 30 Days FREE Trial	$0M	x	x
Lexeo Therapeutics, Inc.	LXEO	Unlock Forecast - 30 Days FREE Trial	$271M	-0,4x	2,0x
Maze Therapeutics, Inc.	MAZE	Unlock Forecast - 30 Days FREE Trial	$696M	x	2,7x
MeiraGTx Holdings plc	MGTX	Unlock Forecast - 30 Days FREE Trial	$693M	-3,4x	20,9x
Metagenomi, Inc.	MGX	Unlock Forecast - 30 Days FREE Trial	$72M	x	0,4x
Moderna, Inc.	MRNA	Unlock Forecast - 30 Days FREE Trial	$9659M	-3,2x	1,0x
NEUROCRINE BIOSCIENCES INC	NBIX	Unlock Forecast - 30 Days FREE Trial	$14639M	42,0x	5,4x
NKGen Biotech, Inc.	NKGN	Unlock Forecast - 30 Days FREE Trial	$4M	-0,1x	-0,2x
NKGen Biotech, Inc.	NKGNW	Unlock Forecast - 30 Days FREE Trial	$1M	x	0,0x
Neumora Therapeutics, Inc.	NMRA	Unlock Forecast - 30 Days FREE Trial	$271M	-3,9x	1,5x
NOVAVAX INC	NVAX	Unlock Forecast - 30 Days FREE Trial	$1417M	3,4x	37,7x
Ocugen, Inc.	OCGN	Unlock Forecast - 30 Days FREE Trial	$298M	-4,3x	18,7x
Omega Therapeutics, Inc.	OMGA	Unlock Forecast - 30 Days FREE Trial	$9M	-0,7x	0,8x
Omega Therapeutics, Inc.	OMGAQ	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
VivoSim Labs, INC.	ONVO	Unlock Forecast - 30 Days FREE Trial	$35M	-0,4x	95,9x
Outlook Therapeutics, Inc.	OTLK	Unlock Forecast - 30 Days FREE Trial	$73M	-0,2x	-2,3x
PALISADE BIO, INC.	PALI	Unlock Forecast - 30 Days FREE Trial	$4M	-0,2x	0,7x
Passage BIO, Inc.	PASG	Unlock Forecast - 30 Days FREE Trial	$23M	-0,6x	0,6x
Vaxcyte, Inc.	PCVX	Unlock Forecast - 30 Days FREE Trial	$4403M	-20,4x	1,4x
BiomX Inc.	PHGE	Unlock Forecast - 30 Days FREE Trial	$14M	1,5x	0,7x
Pluri Inc.	PLUR	Unlock Forecast - 30 Days FREE Trial	$-4M	-1,4x	-9,1x
Protalix BioTherapeutics, Inc.	PLX	Unlock Forecast - 30 Days FREE Trial	$120M	19,1x	2,4x
PharmaCyte Biotech, Inc.	PMCB	Unlock Forecast - 30 Days FREE Trial	$7M	-2,6x	0,2x
Prime Medicine, Inc.	PRME	Unlock Forecast - 30 Days FREE Trial	$500M	-1,5x	8,2x
PROKIDNEY CORP.	PROK	Unlock Forecast - 30 Days FREE Trial	$-62M	x	0,0x
Poseida Therapeutics, Inc.	PSTX	Unlock Forecast - 30 Days FREE Trial	$926M	-9,6x	10,6x
Pelthos Therapeutics Inc.	PTHS	Unlock Forecast - 30 Days FREE Trial	$M	x	x
QIAGEN N.V.	QGEN	Unlock Forecast - 30 Days FREE Trial	$10692M	x	3,0x
Quince Therapeutics, Inc.	QNCX	Unlock Forecast - 30 Days FREE Trial	$86M	-1,7x	7,4x
Replimune Group, Inc.	REPL	Unlock Forecast - 30 Days FREE Trial	$932M	-3,8x	2,2x
REPLIGEN CORP	RGEN	Unlock Forecast - 30 Days FREE Trial	$6531M	8219,1x	3,3x
REGENXBIO Inc.	RGNX	Unlock Forecast - 30 Days FREE Trial	$499M	-1,8x	2,3x
Relay Therapeutics, Inc.	RLAY	Unlock Forecast - 30 Days FREE Trial	$707M	-2,0x	1,1x
Revolution Medicines, Inc.	RVMD	Unlock Forecast - 30 Days FREE Trial	$7134M	-11,1x	3,4x
Revolution Medicines, Inc.	RVMDW	Unlock Forecast - 30 Days FREE Trial	$16M	x	0,0x
RECURSION PHARMACEUTICALS, INC.	RXRX	Unlock Forecast - 30 Days FREE Trial	$2019M	-4,7x	2,2x
SAB Biotherapeutics, Inc.	SABS	Unlock Forecast - 30 Days FREE Trial	$24M	-2,3x	1,1x
SAB Biotherapeutics, Inc.	SABSW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Sana Biotechnology, Inc.	SANA	Unlock Forecast - 30 Days FREE Trial	$697M	-2,1x	5,7x
Scilex Holding Co	SCLX	Unlock Forecast - 30 Days FREE Trial	$62M	-0,4x	-0,3x
Scilex Holding Co	SCLXW	Unlock Forecast - 30 Days FREE Trial	$25M	x	-0,1x
Scinai Immunotherapeutics Ltd.	SCNI	Unlock Forecast - 30 Days FREE Trial	$9674M	-287,8x	1231,2x
SANGAMO THERAPEUTICS, INC	SGMO	Unlock Forecast - 30 Days FREE Trial	$131M	-1,6x	6,7x
Solid Biosciences Inc.	SLDB	Unlock Forecast - 30 Days FREE Trial	$495M	-0,9x	1,7x
Silexion Therapeutics Corp	SLXN	Unlock Forecast - 30 Days FREE Trial	$4M	x	34,5x
Silexion Therapeutics Corp	SLXNW	Unlock Forecast - 30 Days FREE Trial	$866M	x	-189,1x
Senti Biosciences, Inc.	SNTI	Unlock Forecast - 30 Days FREE Trial	$51M	-1,1x	1,3x
Scholar Rock Holding Corp	SRRK	Unlock Forecast - 30 Days FREE Trial	$4069M	-18,5x	13,0x
Surrozen, Inc./DE	SRZN	Unlock Forecast - 30 Days FREE Trial	$105M	-0,5x	2,2x
Surrozen, Inc./DE	SRZNW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
SUTRO BIOPHARMA, INC.	STRO	Unlock Forecast - 30 Days FREE Trial	$90M	-1,0x	-2,5x
SpringWorks Therapeutics, Inc.	SWTX	Unlock Forecast - 30 Days FREE Trial	$3539M	-9,9x	8,5x
Protara Therapeutics, Inc.	TARA	Unlock Forecast - 30 Days FREE Trial	$131M	-2,1x	0,9x
Tarsus Pharmaceuticals, Inc.	TARS	Unlock Forecast - 30 Days FREE Trial	$2390M	-12,4x	7,2x
TC BioPharm (Holdings) plc	TCBP	Unlock Forecast - 30 Days FREE Trial	$37M	x	34,5x
TC BioPharm (Holdings) plc	TCBPW	Unlock Forecast - 30 Days FREE Trial	$1M	x	1,0x
TC BioPharm (Holdings) plc	TCBPY	Unlock Forecast - 30 Days FREE Trial	$13M	x	12,0x
TScan Therapeutics, Inc.	TCRX	Unlock Forecast - 30 Days FREE Trial	$248M	-4,6x	1,4x
BIO-TECHNE Corp	TECH	Unlock Forecast - 30 Days FREE Trial	$8155M	75,2x	4,0x
Tectonic Therapeutic, Inc.	TECX	Unlock Forecast - 30 Days FREE Trial	$314M	-8,9x	1,1x
Instil Bio, Inc.	TIL	Unlock Forecast - 30 Days FREE Trial	$182M	-1,1x	1,3x
Tenaya Therapeutics, Inc.	TNYA	Unlock Forecast - 30 Days FREE Trial	$184M	-2,5x	1,9x
Tourmaline Bio, Inc.	TRML	Unlock Forecast - 30 Days FREE Trial	$688M	-3,5x	2,7x
Turnstone Biologics Corp.	TSBX	Unlock Forecast - 30 Days FREE Trial	$8M	-0,1x	0,6x
Taysha Gene Therapies, Inc.	TSHA	Unlock Forecast - 30 Days FREE Trial	$919M	-3,0x	3,7x
TITAN PHARMACEUTICALS INC	TTNP	Unlock Forecast - 30 Days FREE Trial	$8M	-0,5x	4,5x
Tevogen Bio Holdings Inc.	TVGN	Unlock Forecast - 30 Days FREE Trial	$168M	x	-29,3x
Tevogen Bio Holdings Inc.	TVGNW	Unlock Forecast - 30 Days FREE Trial	$11M	x	-1,9x
Twist Bioscience Corp	TWST	Unlock Forecast - 30 Days FREE Trial	$1487M	-12,6x	3,1x
Voyager Acquisition Corp./Cayman Islands	VACH	Unlock Forecast - 30 Days FREE Trial	$-1436M	x	0,0x
Voyager Acquisition Corp./Cayman Islands	VACHU	Unlock Forecast - 30 Days FREE Trial	$-1585M	x	0,0x
Vericel Corp	VCEL	Unlock Forecast - 30 Days FREE Trial	$1655M	232,9x	5,4x
Vigil Neuroscience, Inc.	VIGL	Unlock Forecast - 30 Days FREE Trial	$384M	-1,1x	9,3x
Vir Biotechnology, Inc.	VIR	Unlock Forecast - 30 Days FREE Trial	$732M	-2,0x	0,8x
VivoSim Labs, INC.	VIVS	Unlock Forecast - 30 Days FREE Trial	$3M	x	0,3x
Vor Biopharma Inc.	VOR	Unlock Forecast - 30 Days FREE Trial	$246M	-0,6x	3,9x
Vaxart, Inc.	VXRT	Unlock Forecast - 30 Days FREE Trial	$87M	-0,9x	2,7x
Voyager Therapeutics, Inc.	VYGR	Unlock Forecast - 30 Days FREE Trial	$248M	570,6x	1,0x
WINDTREE THERAPEUTICS INC /DE/	WINT	Unlock Forecast - 30 Days FREE Trial	$18M	-0,4x	4,2x
X4 Pharmaceuticals, Inc	XFOR	Unlock Forecast - 30 Days FREE Trial	$8M	6,4x	0,4x
Zivo Bioscience, Inc.	ZIVO	Unlock Forecast - 30 Days FREE Trial	$57M	-31,3x	-2,0x
Zura Bio Ltd	ZURA	Unlock Forecast - 30 Days FREE Trial	$131M	5,0x	0,9x

Frequently Asked Questions - VivoSim Labs, INC. Stock Forecast

How accurate are VivoSim Labs, INC. stock predictions?

Our AI model demonstrates 33% historical accuracy for ONVO predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence VivoSim Labs, INC. stock price forecasts?

Our analysis considers VivoSim Labs, INC.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is VivoSim Labs, INC. a good investment in 2025?

Based on our AI analysis, VivoSim Labs, INC. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are VivoSim Labs, INC. forecasts updated?

VivoSim Labs, INC. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced VivoSim Labs, INC. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for VivoSim Labs, INC. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...

Cookie Settings

Welcome !

VivoSim Labs, INC. (ONVO) AI Stock Price Forecast & Investment Analysis ⛶Full Screen

VivoSim Labs, INC. Stock Price Chart and Technical Analysis